Dave Fuehrer, cofounder and CEO of GRYT Health, a digital healthcare company that provides patient research support educational services focused in the oncology space, discusses his story, the challenges in setting up GRYT Health’s business model, its use of technology to enhance the patient experience and much more.

Living and Leading the Patient Experience

Atul Vashishta, founder and CEO of Supply Wisdom, a company that delivers continuous risk intelligence, discusses his story in starting up the business, how he identified early risk indicators for Covid disruption, industry approaches to cybersecurity and plenty more.

Predicting Supply Risk and Disruption

Mike Townsend, research director of life sciences commercial strategies at the International Data Corporation (IDC), a global provider of market intelligence, advisory services and events for various sectors, discusses how revenue management is influenced by factors such as industry reputation, advances in cloud technology and data analytics, the complex drug coverage picture, new supply chain regulations and more.

Managing Revenue in a Tech-driven World

Tim Kress-Spatz, president at DoseID Consortium, an industry group established to unify an approach to serialized, radio-frequency identification (RFID) pharmaceutical products, and co-founder of Kit Check, which helps provide visibility into medication supply management, discusses RFID’s promise in downstream supply-chain tracking, the importance of interoperability in tracing drugs, reducing the inventory management burden for hospitals, and more.

Vision and Visibility: RFID’s Emergence in Healthcare

Jen Grogono, founder and CEO of uStudio, which works with pharma companies to streamline information, updates and training for their sales professionals, discusses the challenges for drugmakers in keeping employees in the know—and how the use of adaptive communication models like enterprise, or internal, podcasting can help connect company culture and address the changing messaging needs of increasingly dispersed workforces.

Enterprise Podcasting in Pharma

Chris DiCostanzo, VP of patient engagement solutions for OptimizeRx, a provider of digital health tools and strategies to improve drug affordability and adherence, discusses the challenges encountered most today in therapy initiation and maintaining treatment—and how new approaches in brand communication and messaging, including the use of AI-driven real-world evidence, can deliver benefits to patients, physicians and manufacturers at the point-of-care.

The Pursuit of Precision in Point-of-Care Support

Brent Ragans, president of Ferring Pharmaceuticals US, a specialty biopharmaceutical company involved in various treatment areas, including reproductive medicine and maternal health, explores the stigma surrounding infertility, the challenge of improving patient access to IVF treatment and care, and legislative developments addressing hopeful health coverage and eligibility reform in this area.

Democratizing Reproductive Treatments for All

The PC Podcast catches up with Chip Davis, president and CEO of the Healthcare Distribution Alliance (HDA), who shares candid perspectives on the role of pharmaceutical distributors during the pandemic, how HDA members are navigating today’s wider supply-chain disruption and the latest actions from the sector in achieving critical sustainability goals.

A Check-in with Chip Davis

Pouria Sanae, CEO of ixlayer, a technology company, explains the obstacles surrounding the distribution of remote lab tests  pre-, during and post-pandemic, the shift to at-home Covid screenings, the logistical challenges in collaborating with different US regions, and the concept of the “pre-patient” model for preventative care.

Diagnostic Testing During a Pandemic

David Coman, CEO of Science 37, a decentralized clinical trials platform company, discusses his organization’s recent public debut via the SPAC route, how that’s powering its mission to enable universal and diverse access to clinical research, and the potential of “agile clinical trial” designs in disrupting the future drug development landscape for the better.

Diversity and Disruption in Clinical Research

AJ Loiacono, CEO of Capital Rx, which doubles as pharmacy benefit manager (PBM)and health tech firm, dives into his inspiration for entering the PBM arena, the company’s formula for providing more transparency into drug pricing and the importance of simplifying complex administrative and workflow barriers between pharmacies, payers and other entities to keep up with the future of healthcare.

Solving the Drug Pricing Conundrum

Casey McTigue, managing director of professional services at SRS Acquiom, which provides support for M&A transactions across various sectors, discusses the firm’s recently released study on milestone payment and earnout trends in life sciences M&A, including during Covid; their influence on sales and development milestones; how parties account for transaction disputes; and the potentially shifting power dynamic in pharma dealmaking post-pandemic.

M&A Milestones: The Covid Impact

Matthew W. Reynolds, vice president, real-world solutions, at IQVIA, dives into the implications of FDA’s recent draft guidance on using real-world data from electronic health records and medical claims data to aid in drug development and regulatory decision-making—and shares specific steps pharma companies can take to assess the relevance and quality of their data in light of this guidance.

RWD ‘Fitness’ Steps for Pharma

Ardy Arianpour, the outspoken CEO and co-founder of health-tech company Seqster, details his personal motivation and entrepreneurial quest to topple data-access barriers in digital health, the chance meeting with Bill Gates that helped shape his platform's mission and explains the concept of “person-centric interoperability” in transforming “real-time” efforts in patient engagement.

Seeking Better Patient Engagement

Patty Riskind, CEO of Orbita, discusses the origins of the platform, her inspiration in joining the team, how in fact the company uses conversational artificial intelligence (AI) to its advantage and the future outlook of this technology.

Enhancing Conversational AI

Sandra Anderson, senior vice president of commercialization and strategy at Innomar Strategies, a service provider in the Canadian specialty biopharma space, discusses the process in bringing a product to market in Canada, how Innomar guides patients along their patient journey, the logistical challenges that come with vaccine distribution, and plenty more.

Promoting Effective Patient Support

Glenn Carroll, safety leader and principal at Deloitte Consulting, a firm that has collaborated with a Big Pharma company on an AI software-as-a-service platform, details the obstacles that drug safety providers face today, and how the competitive landscape is evolving as new entrants join the field.

Advancing Pharmacovigilance

Adham Yehia, co-founder and COO of DrugStoc, a cloud-based pharmaceutical distribution platform that is working to assist healthcare providers (HCPs) across Africa by connecting manufacturers to hospitals and pharmacies, outlines his inspiration for founding the company, along with the logistical obstacles that come with distribution.

Providing Medication Access to Africa

Dennis Wright, senior director of product marketing at Omnicell, a company that provides both a medication management platform along with technology-enabled services, discusses the ongoing issue of medication nonadherence and efficient ways to utilize pharmacists’ expertise in an effort to create an effective supply chain.

Re-evaluating the Role of the Pharmacist

David Sanders, vice president of government affairs & policy at biosimilars company Coherus BioSciences, speaks on the firm’s goal of expanding patient access to cost-effective medication, and his role with Securing America’s Medicines and Supply, a coalition of companies aiming to strengthen the security of the US medical supply chain.

Prioritizing American Manufacturing

Wes Wheeler, president of UPS Healthcare, discusses the notable gains in the temperature-controlled logistics sector, along with the lessons he’s learned as a seasoned veteran in the industry.

The Evolution of the Cold Chain Logistics Industry

Andy Udell, North American president at Calliditas Therapeutics, a specialty pharma company, uncovers the complexities surrounding rare disease product commercialization, while also shedding light on outreach strategies that help spread awareness of new medications.

Achieving Success in the Rare Disease Space

Pete Stark, EVP of commercial strategy at Veeva Systems, a cloud-based software provider, digs into strategies for maintaining data privacy, and how data has transformed across the pharma industry.

Safely Collecting Patient Data

Sanjay Sharma, chairman and CEO of Roambee, a supply chain visibility and intelligence company, uncovers ways to provide pharma supply chain security as it pertains to protection from counterfeit goods, along with ways to properly monitor temperature-sensitive products.

Optimizing the Pharma Supply Chain

Updesh Dosanjh, practice leader for the pharmacovigilance (PV) technology solutions business unit at IQVIA, discusses the ways in which PV plaforms decrease the time, expense, and risk involved in manual reporting, along with how technologies are impacting these types of workloads.

Using Pharmacovigilance Platforms to One’s Advantage

Tom Cotter, executive director of Healthcare Ready, a non-profit organization, dives into ways to facilitate solutions in the face of a disaster, including how to protect patient access to medication during these times of crisis.

Protecting Patient Access to Medication in the Midst of Crisis

Gregg Gorniak, senior director of manufacturer operations & data services at AmerisourceBergen, provides a history and overview of the Drug Supply Chain Security Act (DSCSA), including how prepared the pharma supply chain is in successfully implementing its requirements.

The DSCSA Overview

In this exclusive PC Podcast interview, Susanne Katus, SVP, market leader, corporate secretary at Datamaran, a platform that monitors and analyzes risk factors, dives into the growing number of environmental, social, and governance (ESG) regulations impacting these aforementioned businesses; where the responsibility lies for them in terms of ESG compliance; what can be done in order for these corporations to be ahead of the game; and why ESG should be a top priority.

ESG Evolution

In this exclusive PC Podcast interview, Jason Cook, Cardinal Health’s director of operations, explores the importance of having a comprehensive contingency plan, especially before weather-related disruptions begin; what needs to be done by pharma companies post-disaster in order to not only create a stronger strategy for next time, but to also have customers feel seen and included throughout that process; advice for effectively communicating with customers; and how technology plays a role in helping to predict or better prepare for these storms and disasters.

Supply Chain Safeguards

In this exclusive PC Podcast interview—sponsored by Alltrista—Raphael Chin Fo Sieeuw, DHL’s VP of life sciences and healthcare, Americas, uncovers how his plethora of experience successfully prepared him to perform the required duties in his current position; the latest trends that are helping to reshape and impact the pharma supply chain; what can be done to combat 300 million tons of plastic waste every year that the global healthcare sector generates (according to the World Health Organization); and how the industry can continue to dig itself out of the national drug shortage hole.

Implementing Sustainable Business Practices

In this PC Podcast episode, Editor Nicholas Saraceno reviews the past year by providing a look at five articles that made a splash.

A Year in Review

In this PC Podcast interview that originally aired for Pharmaceutical Executive, Camille Lee, UCB’s SVP and US head of immunology, dives into the history behind UCB's work in psoriasis;
the significance behind UCB announcing the commercial availability of Bimzelx for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy; how Bimzelx Navigate can be utilized as a resource for patients on this drug; and what listeners should keep an eye out for in terms of UCB's rheumatology pipeline.

Treating Psoriasis While Providing Patient Support

In this exclusive PC Podcast interview, Dave DeJean, Systech’s VP of global strategic accounts, dives into the valuable lessons he’s learned along the way, given his three and half decades of experience at Systech; an overview of the Drug Supply Chain Security Act (DSCSA), including its three main pillars; how he would interpret this “Stabilization Period” that the FDA provided this past summer, and what he pharma industry do now during this period in order to avoid penalties later; and whether or not he anticipates the FDA implementing any other sort of delays in the near future in order to help remedy these issues/challenges surrounding the enactment of DSCSA

Complying With the DSCSA

In this exclusive PC Podcast interview, Rob Besse, Archbow Consulting’s VP of distribution services, shares a general overview of how the 3PL process works, using his 20-plus of pharma supply chain experience as added insight; the factors that manufacturers should consider when selecting a 3PL, along with the array of services that a quality 3PL should provide; valuable lessons he believes 3PLs learned during the COVID-19 pandemic that have helped improve efficiencies; and trends affecting the pharma industry that 3PLs be on the lookout for the rest of the year/

A First-Hand Account of 3PLs

In this exclusive PC Podcast interview, Brandon Newman, Xevant’s CEO and founder, explores the implications of the Inflation Reduction Act’s price negotiation provisions, and how these could result in ripple effects across the healthcare system; the role that pharmacy benefit managers (PBMs) and other intermediaries' play when it comes to determining drug costs, and how spread pricing is involved; how Xevant helps improve drug cost transparency efforts; and strategies for affordability Newman would offer the pharma industry that can be implemented immediately.

Popular tracks by Pharmaceutical Commerce Magazine